Hepatitis C virus (HCV) is an enveloped positive-strand RNA virus and the sole member of the genus Hepacivirus, within the Flaviviridae. Approximately 170 million individuals are infected with HCV worldwide, and the majority are at risk of developing serious progressive liver disease. The principal reservoir for viral replication is believed to be hepatocytes within the liver, and until recently, minimal information was available on the mechanism(s) of HCV entry. However, the last 3 years have seen several advances that contribute to our ability to study HCV hepatotropism. First, the development of the retrovirus pseudoparticle system, in which cell entry is dependent upon the expression of HCV glycoproteins (HCVpp) (4, 20), and secondly, the ability of the JFH strain of HCV to release infectious particles in cell culture (HCVcc) (25, 51, 55) .
Hepatitis C virus (HCV) is an enveloped positive-strand RNA virus and the sole member of the genus Hepacivirus, within the Flaviviridae. Approximately 170 million individuals are infected with HCV worldwide, and the majority are at risk of developing serious progressive liver disease. The principal reservoir for viral replication is believed to be hepatocytes within the liver, and until recently, minimal information was available on the mechanism(s) of HCV entry. However, the last 3 years have seen several advances that contribute to our ability to study HCV hepatotropism. First, the development of the retrovirus pseudoparticle system, in which cell entry is dependent upon the expression of HCV glycoproteins (HCVpp) (4, 20) , and secondly, the ability of the JFH strain of HCV to release infectious particles in cell culture (HCVcc) (25, 51, 55) .
Early studies with a truncated soluble version(s) of HCV E2 (sE2) allowed the identification of a number of interacting cellular proteins, including the tetraspanin CD81 (16, 37) , scavenger receptor class B type I (SR-BI) (43) , and DC-specific ICAM-3-grabbing nonintegrin (DC-SIGN) and the related molecule DC-SIGN(R), or L-SIGN (15, 18, 27, 40) . The availability of HCVpp and infectious HCVcc has provided tools for validating these receptor candidates.
CD81 is a nonglycosylated member of the tetraspanin family of proteins. Both HCVpp and HCVcc infectivities are inhibited by soluble forms of CD81 and by anti-CD81 monoclonal antibodies (MAbs), suggesting that CD81 is required for HCV infection (6, 20, 25) . Definitive experiments showing that expression of CD81 in a CD81-negative human liver cell line, HepG2, confers infectivity support a critical role of CD81 in HCV cell entry (24, 25, 54, 55) .
SR-BI is expressed within the liver, steroidogenic tissue, and macrophages and is considered to be the major receptor for high-density lipoprotein (HDL) (23) . SR-BI mediates the traffic of cholesterol to and from lipoproteins by selective cholesterol uptake, cholesterol efflux, and receptor-mediated endocytosis (1, 34, 42, 44) . The SR-BI gene gives rise to at least two mRNA splice variants. The SR-BII isoform differs from SR-BI at the C terminus, which is reported to confer intracellular localization on SR-BII (14, 33, 52) .
Experiments to validate the role of SR-BI in HCV infection have proven difficult, since all cell types studied to date express SR-BI, and small interfering RNA silencing has a modest effect on HCVpp infectivity (6, 24, 48) . The native lipoprotein ligands have differential effects on HCV infectivity: HDL enhances infectivity, low-density (LDL) and very low-density lipoproteins (VLDL) have no effect (5, 48) , and oxidized LDL abrogates infectivity (50) , suggesting a complex interplay between SR-BI, lipoproteins, and HCV. Treatment of target cells with inhibitors of SR-BI-dependent selective cholesterol uptake, BLT-2 and BLT-4, abrogates HDL-enhanced viral infectivity (5, 12) , suggesting a role for this selective process in HCV entry. A recent study demonstrated that anti-SR-BI and anti-CD81 antibodies inhibit JFH infectivity in a synergistic manner, suggesting cooperativity between the receptors in mediating viral infection (21) .
In human plasma, HCV particles have been reported to be complexed with lipoproteins, suggesting an indirect interaction of the virus with lipoprotein receptors (2, 28, 35, 45) . However, the significance of the virus-lipoprotein interaction for the virus life cycle is unknown. Several laboratories have purified HCV from plasma to study virus-cell interactions; however, these experiments are difficult to interpret, since they are unable to measure viral infectivity. The recent observation that HCVcc is infectious for uPA-SCID mice with transplanted human hepatocytes provides a source of plasma that is infectious for cultured cells and allows in vitro experimentation (26, 31, 32) .
HCVpp and HCVcc enter cells via a pH-and clathrin-dependent endocytic pathway (7, 10, 20, 30, 47) . SR-BI internalization remains poorly understood, but SR-BII is reported to endocytose via a clathrin-dependent pathway, making it an attractive target for the study of HCV attachment and entry (13) . In this study, we demonstrate that HCV sE2 can interact with human SR-BI and SR-BII expressed in CHO cells. Increased expression of SR-BI and SR-BII in Huh-7.5 cells enhances the infectivity of cell culture-and plasma-derived J6/ JFH, suggesting that endogenous levels of these receptors limit HCV infection. Anti-SR-BI antibodies inhibit the infectivity of cell culture-and plasma-derived J6/JFH, supporting a critical role for SR-BI/II in HCV infection.
MATERIALS AND METHODS
Cells, antibodies, and plasmids. 293T and Chinese hamster ovary (CHO) cells were obtained from the American Type Culture Collection and propagated according to their recommendations. Huh-7.5 cells (provided by Charles Rice, The Rockefeller University, New York) (8) were propagated in Dulbecco's modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% nonessential amino acids. All cells were grown at 37°C in 5% CO 2 . CHO cells stably expressing SR-BI were generated and propagated as previously described (28) . Anti-SR-BI sera were generated by immunizing rabbits (Mirus Corporation, Madison, WI) with a pcDNA expression vector encoding fulllength SR-BI (28) . Antisera specific for the SR-BI and SR-BII C-terminal peptides were generated by immunizing rabbits with peptides corresponding to amino acids 496 to 509 of murine SR-BI (46) and amino acids 493 to 514 of human SR-BII (33) . The cloning of pCM5 expressing murine SR-BI tagged at the N terminus with enhanced green fluorescent proteins (eGFP) (provided by Deneys van der Westhuyzen, University of Kentucky) was previously reported (13, 14) .
Generation of lentiviral vectors expressing SR-BI and SR-BII. Fully sequenced human SR-BI and SR-BII genes were transfer cloned into pTRIP lentiviral packaging plasmids capable of directing their packaging into TRIP lentiviral gene delivery vectors (53) .
HDL-SR-BI interactions. Labeling of HDL with the fluorescence probe 1,1Ј-dioctadecyl-3,3,3-,3-tetramethylindocarbocyanine perchlorate (DiI) was carried out as previously described (38) . Briefly, 5 ϫ 10 5 CHO or CHO-SR-BI cells in suspension were preincubated with an irrelevant rabbit serum or with the anti-SR-BI serum for 1 h at 4°C, washed, and incubated with DiI-labeled HDL (50 g protein/ml) for 1 h at 4°C. The cells were fixed with 5% formalin neutral buffered solution (Sigma), and DiI fluorescence was measured by flow cytometry (Epics XL; Beckman Coulter).
Expression of SR-BI and SR-BII. TRIP lentiviruses expressing SR-BI, SR-BII, or CD9 were generated by cotransfecting 293T cells with plasmids encoding vesicular stomatitis virus G protein, human immunodeficiency virus Gag-Pol, and the pTRIP construct (1:3:3 ratio). CHO and Huh-7.5 cells were seeded at 8 ϫ 10 5 cells per well in a six-well plate and infected 24 h later with the packaged lentivirus diluted in DMEM supplemented with 3% FBS. After 12 h, the cells were washed, trypsinized, and seeded into appropriate plates for HCV infection or flow cytometry. Murine eGFP-SR-BI was expressed in Huh-7.5 cells by transient transfection with Lipofectamine (Invitrogen, California)-based delivery of plasmid into cells.
Flow cytometry. Cell surface expression of SR-BI/II was monitored by live-cell staining with antisera specific for the SR-BI extracellular region and preimmune or irrelevant-species isotype-matched antibodies, as previously described (17) . To detect the intracellular C-terminal regions of SR-BI and SR-BII, cells were fixed with 1% paraformaldehyde and permeabilized with 0.05% saponin prior to being stained with specific antisera as previously described (8, 20) . sE2 binding to cells was assayed as previously described (50) . Analyses were performed using a FACScalibur flow cytometer (BD Biosciences) and FlowJo software (Tree Star, San Carlos, CA).
HCVcc genesis and infection assays. J6/JFHcc and JFHcc particles were generated as previously described (25) . Briefly, RNA was transcribed in vitro from full-length genomes using the Megascript T7 kit (Ambion, Austin, TX) and electroporated into Huh-7.5 cells. Seventy-two and 96 h postelectroporation, the supernatants were collected, pooled, and stored at Ϫ80°C. Three uPA ϩ/ϩ SCID mice were transplanted with human hepatocytes and infected with cell culturederived J6/JFH by intraperitoneal injection, as described previously (26, 32) . COBAS Ampliprep TaqMan analysis (Roche Diagnostics, Mannheim, Germany) of mouse plasma demonstrated high-level infection, with a mean viremia of 4.72 ϫ 10 6 IU/ml within 2 weeks. An acute-phase plasma-derived virus stock was generated by subsequent twice-weekly blood sampling for 4 weeks, pooled, aliquoted, and stored at Ϫ80°C. Huh-7.5 cells were seeded at 1.5 ϫ 10 4 cells per well in 48-well plates and the following day were infected with virus diluted in 3% FBS-DMEM for 1 hour. At 72 h postinoculation, viral infection was detected by methanol fixation and staining for NS5A antigen using the anti-NS5A MAb 9E10 and Alexa 488-conjugated anti-mouse immunoglobulin G (IgG) (Invitrogen, California) (25) . Huh-7.5 cells expressing murine eGFP-SR-BI (48 h posttransfection) were infected with JFHcc as described above, and after 72 h, the infected cells were visualized with anti-NS5A MAb and Alexa 633-conjugated anti-mouse IgG (Invitrogen, California).
RESULTS

SR-BI and SR-BII can interact with HCV sE2
. SR-BI expression in CHO cells confers sE2 binding (43) . To address whether SR-BII can interact with sE2, CHO cells were transduced with lentiviral vectors expressing human SR-BI or SR-BII and transgene expression was assessed by anti-SR-BI serum reactivity. Antisera were raised by genetic immunization of rabbits with a plasmid encoding full-length SR-BI and were shown to bind CHO cells stably expressing SR-BI (Fig. 1A) . HCV sE2 strain H77-bound CHO cells expressed SR-BI, showing saturation at 30 g/ml (Fig. 1B) . Anti-SR-BI serum bound to CHO cells transduced with TRIP-SR-BI or TRIP-SR-BII, confirming expression of the receptors at the cell surface (Fig. 1C) . SR-BI and SR-BII bound comparable levels of sE2 at 30 g/ml (Fig. 1D) , suggesting that both molecules have the capacity to bind and mediate HCV infection.
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. To study the effect of SR-BI/II overexpression on viral infectivity, Huh-7.5 cells were transduced with the TRIP viruses characterized in Fig. 1 . Live-cell staining with the anti-SR-BI antiserum demonstrated ϳ3-fold and ϳ1.8-fold increases in cell surface-expressed SR-BI and SR-BII, respectively (Fig. 2) . C-terminus-specific antibodies capable of differentiating between SR-BI and SR-BII demonstrated increased reactivity with permeabilized cells, confirming expression of the differentially spliced receptors (Fig. 2) . SR-BI/II overexpression did not affect cell proliferation (data not shown). As controls, Huh-7.5 cells were transduced to Parental and transduced cells were studied for the ability to support J6/JFHcc infection. We previously noted that the time allowed for virus adsorption can affect HCVcc infectivity, suggesting that viral attachment and/or internalization is slow in Huh-7.5 cells (30) . We compared the abilities of the parental and transduced cells to support J6/JFH infection with increasing times of viral adsorption from 1 to 8 h. Infectivity for parental cells increased linearly over time, with a rate of 8,800 infections/h/ml (Fig. 3A) . Overexpression of SR-BI increased J6/JFH infectivity approximately threefold and significantly increased the rate of infection, 22,360 infections/h/ml. In contrast, overexpression of SR-BII increased J6/JFH infectivity 2.5-fold with no significant change in the rate of infection, 11,280 infections/h/ml. Huh-7.5 cells overexpressing CD9 and eGFP murine SR-BI showed no change in susceptibility to HCVcc infection (data not shown). To determine if the same result was observed with a different strain of HCV, we assessed the infectivity of JFH-1 for parental and transduced Huh-7.5 cells following a 1-h period of adsorption. JFH infectivity for SR-BI-and SR-BII-overexpressing cells increased 18-and 6-fold, respectively, compared to parental cells (Fig. 3B) . Several independent JFH and J6/JFH viral stocks showed the same boosting of infectivity, with JFH being more sensitive to SR-BI/II expression levels than J6/JFH (data not shown). The increased infectivity of J6/JFH and JFH for cells overexpressing SR-BI and SR-BII demonstrates that the level(s) of both receptors limits HCV infection of Huh-7.5 cells.
Overexpression of SR-BI/II increased the size of J6/JFHand JFH-infected cell foci; this was particularly striking for JFH infection (Fig. 4) . At 72 h, a focus of infected cells (a group of four or more infected cells) represents "local" virus spread from an initial primary infection event. We interpret the focus count to represent the number of primary infection events and the infected-cell count to reflect primary and secondary infection events. We observed a threefold increase in the number of J6/JFH-infected Huh-7.5 TRIP SR-BI cells compared to parental cells, with a twofold increase in infected foci, whereas JFH infection of Huh-7.5 TRIP SR-BI led to an 18-fold increase in the number of infected cells, with a 5-fold increase in the number of foci. These data suggest that increased SR-BI/II levels enhance HCV infectivity by promoting secondary/local virus spread, in addition to increasing the number of primary infection events.
Scavenger receptor BI and BII expression levels modulate plasma-derived J6/JFH infectivity. The observation that J6/ JFH is infectious for uPA-SCID mice with transplanted human hepatocytes provides us with a source of infectious plasma for infectivity studies (31) . Transplanted hepatocytes within the chimeric mice secrete human lipoproteins (32) , providing virus that closely mimics the virus-lipoprotein complexes circulating in HCV-infected patients. We tested the infectivity of plasmaand cell culture-derived J6/JFH for parental and transduced Huh-7.5 cells. Overexpression of SR-BI and SR-BII increased the infectivity of plasma-derived J6/JFH by 4-fold and 2.5-fold, respectively (Fig. 5A) , consistent with the scavenger receptormediated enhancement of J6/JFH. Maillard and colleagues (28) suggested that plasma-derived HCV bound SR-BI independently of the viral glycoproteins. To test this model, we investigated the infectivity of plasma-and cell culture-derived J6/JFH for Huh-7.5 cells in the presence of a neutralizing anti-E2 MAb, C1 (25) . Infectivity of plasma-and cell culturederived J6/JFH was neutralized by MAb C1, demonstrating that both sources of virus infect cells in an E2-dependent manner (Fig. 5B) .
Anti-SR-BI antibodies inhibit cell culture-and plasma-derived HCV infectivity. We assessed whether anti-SR-BI antibodies would modulate the ability of Huh-7.5 cells to support HCV replication. The polyclonal anti-SR-BI serum bound to Huh-7.5 cells and inhibited plasma-and cell culture-derived J6/JFH infectivity ( Fig. 6A and B) . Titration of the anti-SR-BI serum demonstrated a 50% neutralization endpoint of 1:1,550 for J6/JFHcc infection of Huh-7.5 cells (data not shown). Since 
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we (17, 29, 54 ) and others (6, 24) have reported on the critical role of CD81 in HCV entry, we confirmed that infectivity of J6/JFH from both sources was inhibited with an anti-CD81 monoclonal antibody (MAb M38). Several reports have demonstrated that HDL interaction with SR-BI can promote HCV infectivity (5, 12, 48, 49) . Since hepatoma cells, including Huh-7, have been reported to assemble and secrete ApoA-containing high-density lipoprotein particles (9, 11, 19) , HCV entry into Huh-7.5 may occur via lipoprotein-dependent and/or -independent pathways. In an effort to understand how the anti-SR-BI serum inhibits viral infectivity, we screened the serum for inhibition of HDL and sE2 binding to CHO-SR-BI. The antiserum inhibited HDL and sE2 interaction with SR-BI ( Fig. 6C and D) , suggesting that both activities may contribute to the neutralizing capacity of the polyclonal sera.
DISCUSSION
We have demonstrated that human SR-BI and SR-BII confer sE2 binding to CHO cells and, when overexpressed in Huh-7.5 cells, increase susceptibility to HCV infection. Antibodies specific for SR-BI could inhibit the infectivity of cell culture-and plasma-derived HCV, suggesting a critical role for the receptors in the HCV life cycle. Our findings were facilitated by the genesis of lentiviral vectors expressing SR-BI/II and the availability of antisera targeting both the extracellular regions and the C-terminus-specific regions of the two isoforms.
Overexpression of SR-BI and -II in Huh-7.5 cells significantly increased their susceptibility to cell culture-and plasmaderived HCV, suggesting that SR-BI/II density plays an important role in HCV infection. Similar observations have been reported for CD4 and chemokine receptor expression levels influencing human immunodeficiency virus cell entry (3, 39) . Enhanced expression of SR-BI increased the rate of J6/JFH infection, whereas increased SR-BII expression had no detectable effect(s) on the rate of virus infection. These differences may reflect the altered trafficking profiles reported for SR-BI and SR-BII and may offer alternative routes of entry into Huh-7.5 cells. It is noteworthy that Huh-7.5 cells naturally express both SR-BI and SR-BII, as detected by the C-terminus-specific antibodies (Fig. 2) . Overexpression of SR-BI/II enhanced JFH infectivity to a much greater extent than J6/ JFH; 18-fold and 3-fold, respectively (Fig. 3) , suggesting strainspecific variation within genotypic clades. We reported a similar observation with HCVpp expressing diverse glycoproteins showing altered interaction(s) with rodent CD81 expressed in HepG2 cells, supporting a model of glycoprotein variants with different affinities for the coreceptors (17) . Since J6/JFH and JFH differ in their Core-NS2 regions, it is possible that the observed differences may be due to an altered affinity of the envelope proteins for SR-BI/II.
Murine SR-BI and SR-BII have altered localization and trafficking profiles that are directed by their C-terminal domains (13, 42, 44) . Our data are consistent with these reports, demonstrating that human SR-BII is predominantly expressed within the cell and shows reduced expression at the cell surface compared to SR-BI ( Fig. 2 and data not shown) . The reduced enhancement of infection by SR-BII compared to SR-BI most likely reflects its lower cell surface expression (Fig. 2) . Our data show comparable levels of sE2 binding to CHO-expressed SR-BI and SR-BII, suggesting that the C-terminal region of SR-BI/II has no effect(s) on sE2 or ligand interactions with the extracellular region. However, at the present time, it is unclear whether sE2 is a reliable predictor of viral-SR-BI/II interactions. HCV particles are likely to interact with SR-BI/II and other components of the receptor complex in a cooperative manner that may depend on the extra-and intracellular regions of the coreceptors. Our data suggest that overexpression of either isoform does not affect expression of the other. However, we have been unable to study the localization and trafficking of heterologous SR-BI/II in the transduced cell lines, since N-terminal tagging of both receptors affects their localization (data not shown). Hence, we cannot rule out the possibility that overexpression of SR-BII may have consequences for SR-BI localization/trafficking and vice versa. SR-BI has been reported to form oligomers to facilitate selective cholesterol uptake (41) . It will be interesting to ascertain if SR-BI/II can form hetero-oligomers and whether they act cooperatively to facilitate HCV infection.
Infection of the transduced cells resulted in increased size of infected cell foci that was particularly apparent in the JFHinfected cultures, suggesting improved local virus spread in the presence of excess SR-BI/II (Fig. 4) . Current experiments suggest that HCV can be transmitted within a culture by extracellular virus infection of naive cells and through cell-cell contact(s) (J. M. Timpe and Z. Stamataki, unpublished observations), suggesting that SR-BI/II may promote the latter route of transmission. An increased proliferation rate of the Huh-7.5 SR-BI/II cells cannot explain the increased focal size, since the transduced cells showed no proliferation advantage (data not shown). JFH has a reduced capacity to assemble or release infectious particles compared to J6/JFH and other chimeric viruses (22, 36, 55) . Zhong et al. (56) reported that long-term propagation of JFH in cell culture generated an adaptive variant that showed enhanced particle infectivity and transmission within a culture. It will be interesting to compare the infectivity and transmission of the wild type and the adaptive JFH variant in parental and SR-BI/II-transduced cells to ascertain if the reduced infectivity of JFH particles is compensated for by overexpressing SR-BI/II. Our data suggest that overexpression of SR-BI/II not only increases Huh-7.5 cell susceptibility to primary infection, but aids virus spread to adjacent cells, either at the point of the initial infection or after viral replication and de novo virion production.
The ability of the anti-SR-BI serum to inhibit the infectivity of plasma-and cell culture-derived J6/JFH suggests a critical role for SR-BI/II in virus entry. Several reports have demonstrated that HDL interaction with SR-BI can enhance HCV infectivity (5, 12, 48, 49) . Since interactions between the viral glycoproteins, HDL, and SR-BI are likely to play a role in HCV entry, we were interested to know if the "neutralizing" anti-SR-BI antibodies inhibited either of these ligand-receptor interactions. As a model system to study SR-BI in isolation from the other receptor components expressed in human hepatoma cells, we studied sE2 and HDL interaction with SR-BI expressed in CHO cells. The anti-SR-BI serum inhibited sE2 and HDL interaction with SR-BI (Fig. 6 ). These data suggest that anti-SR-BI neutralization of viral infectivity may occur not only by inhibiting E2 binding, but through interference with SR-BI-HDL interactions. Further studies with defined anti-SR-BI MAbs are warranted to elucidate the mechanism(s) of virus neutralization.
There are many reports of HCV being complexed with VLDL/LDL in the plasma of infected patients, suggesting that viruses may interact with lipoprotein receptors indirectly through the associated lipoproteins and not via the virus-encoded glycoproteins (2, 28, 35, 45) . Several recent observations demonstrating that (i) J6/JFH is infectious for uPA-SCID mice with transplanted human hepatocytes (26, 31) , (ii) transplanted hepatocytes within the mice secrete human lipoproteins (32) , and (iii) plasma-derived J6/JFH has an increased specific infectivity and altered buoyant density compared to J6/JFHcc (26) suggest that mouse-derived J6/JFH is the best mimic for the virus-lipoprotein complexes circulating in HCV-infected patients. Our data clearly demonstrate that the infectivities of plasma-and cell culture-derived J6/JFH for SR-BI/II-transduced cells were enhanced to comparable levels (Fig. 5) . Furthermore, the infectivity of virus from both sources was inhibited by antibodies specific for E2 and SR-BI, suggesting a common entry pathway that is limited by SR-BI/II expression (Fig. 6 ).
